Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
International randomized trial of additional treatments for COVID-19 in hospitalized patients
2020-001366-11Phase 4Suspended
- Sponsor
- Fundación para la Investigación Biomédica del Hospital Clínico San Carlos
- Start
- Mar 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of remdesivir, chloroquine, hydroxychloroquine, lopinavir and interferon beta-1a in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Fundación para la Investigación Biomédica del Hospital Clínico San Carlos. Primary endpoint: All-cause mortality. Started Mar 2020; status: suspended.
02
Drugs
remdesivirchloroquinehydroxychloroquinelopinavirinterferon beta-1a
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001366-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001366-11.